[82] The trial reported cumulative occurrence of major adverse cardiovascular events, a primary end-point event of the trial, for 569 of the 8803 patients in the semaglutide group, which were 6.5% of the participants, and for 701 of the 8801 patients in the placebo group, which were 8% of the participants, showing relative 18.8% less major adverse cardiovascular events, such as death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, occurring for participants who had received semaglutide in the trial relative to those who had received placebo over the course of around 48 months, or 34.213.7 months, which was the mean (SD) total duration of the participants in either group's exposure to the placebo or semaglutide during the trial
One bottle lasts approximately 6-8 weeks with daily use
Today I did 30 minutes on the vibration plate, 20 squats Things I wish I knew before starting GLP-1 If youre considering a GLP-1 or already on one, this is what I wish I understood sooner since being on my journey with @Mochi Health Everyones experience is different, and this has been my personal journey over the last year
[5] Understanding the context is essential for both patients and healthcare professionals
